3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Neoplasms
3
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
pertuzumab
3
trametinib
2
palbociclib
2
dabrafenib
2
copanlisib
2
Trastuzumab
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Immunoglobulin G
2
HhAntag691
2
Fluorouracil
2
Disulfides
2
Dasatinib
2
Bevacizumab
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
venetoclax
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
temsirolimus
1
sapanisertib
1
ruxolitinib
1
romidepsin
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
alectinib
×
Genitourinary
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled